Tiotropium Versus Salmeterol For Prevention -Myassignmenthelp.Com

Question: Discuss About The Tiotropium Versus Salmeterol For Prevention? Answer: Introducation Bronchitis on the other hand is developed due to the inflammation of the bronchial tubes accompanied by the over secretion of mucus. The over secretion of mucus eventually leads to blocking of the airways and contribute to difficult air passage during the process of respiration. It has to be understood that smoking is a very important contributing factor that has a profound role in the pathophysiologic development of this respiratory disorder. For the case study, Robert, the patient under consideration had been a chain-smoker for 40 years, smoking can be considered as the origin of the disease he had developed. According to the case study, Robert had been diagnosed with COPD 18 months ago and had been feeling unwell for months befire that as well. Hence, it can be concluded that the onset of manifestations brnchitics and emphysema had begun since a long time. The added burden of smoking excessively had contributed effectively to further deteriorating the disease, along with the age f actor of the patient in the case study. COPD pathway (Vogelmeier et al., 2011) impact of age on COPD (Erb-Downward et al., 2011) Exacerbation of the COPD: An exacerbation can be defined as the sudden worsening or deterioration of the conditions that the patient is going through. In case of COPD, exacerbation can be due to many factors; however the most common contributor is bacterial infection. It generally comprises of sudden acute shortness of breath and altered quantity and consistency of the phlegm. In case of COPD, an exacerbation event can last up-to several days and can effectively complicate the health condition of the patient. In case of an exacerbation of COPD, the airways of the patient go through enhanced inflammation, and coupled with increased mucous production, the gas exchange is impaired effectively (Vogelmeier et al., 2011). There can be many contributing factors that lead to an exacerbation event, along with bacterial, infection, environmental pollution is also another reason for the sudden worsening. With respect to the case study, for Robert, the most important risk factor that might have had a profound role in the development of the exacerbation of the disease is infection. Infection by Streptococcus pneumoniae often leads to further blockage of the airways which contributes to impaired gas exchange and leads to dyspnea. According to the case study, Robert had been a smoker for 40 years and continues to smoke in the present. Hence, the second risk factor for Robert that might have led to exacerbation is smoking (Erb-Downward et al., 2011). It has to be understood that allergens, especially smoke, can irritate the inflamed airways and air sacs resulting in further inflammation. Hence these are the two risk factors behind the exacerbation of COPD experienced by Robert in the case study. Pathophysiology of pneumonia: Pneumonia can be described as the infectious disease facilitates the inflammation of the air sacs and results in overproduction of phlegm. The infection can have either bacterial or viral Origin. During aspiration process the bacterial pathogen enters the body through the airways and colonize the lung parenchyma. On a more elaborative note, it has to be mentioned that the infection mechanism is facilitated by the invasion of the lung parenchyma. The overgrowth of the bacteria in the lung parenchyma provokes the overproduction of intra-alveolar exudates like mucous. It has to be mentioned in this context that the pneumonia infection manifests further as soon as the pathogen reaches the alveoli, the host defences at this point are usually overwhelmed by either the virulence or the inoculum size of the pathogen, and the infection spreads (Musher Thorner, 2014). The community acquired pneumonia (CAP) can be considered as the most commonly reported type and the mechanism of the infection in case of the community acquired pneumonia differs from the other types significantly. The community acquired pneumonia is fundamentally unique from any other type of pneumonia by the fact that it is not associated with the health care facility at all. In case of CAP, the causing organism can be over 100 different types. The most common types of infectious agents in case of the community acquired pneumonia, are bacteria, virus, fungi and even allergens. However, in case of hospital acquired pneumonia is often more severe as it is acquired by the patient during hospice stay, and the causing agent is often antibiotic resistant strains. The patients on ventilators and intensive care units are at the most risk of this type of pneumonia. In case of the health care associated pneumonia the point of acquiring the infection is due to a long term stay in any communit y care setting or any outpatient clinics (Johansson, Kalin, Tiveljung-Lindell, Giske Hedlund, 2010). Pharmacology of the medications administered: It is a selective Beta 2 adrenergic receptor stimulating drug, and the most important function of this medication in case of COPD is of bronchodilation. It has to be mentioned that the stimulation by salbutamol activates the adenyl cyclase which is then transformed into cyclic AMP. The increased concentration of cyclic AMP then in turn relaxes the bronchial smooth muscles and reduces the airway resistance by relaxing the bronchial tubes from trachea to terminal bronchioles (Albert et al., 2011). The contraindications for salbutamol include any patient with a history of hypersensitivity reaction along with any patient with fast history of cardiac tachyarrhythmias. Hence if Robert has had any history of hypersensitivity, Salbutamol will be contraindicated for him. Also salbutamol is a well tolerated drug. yet side effects may occur due to any dosage or administration route error. With respect to this case study, the nursing professional should also be careful if Robert exhibits any signs of tremors special in the hands or any preparation of tachycardia, which is the most frequently reported side effects of salbutamol (Bischoff et al., 2011). Budesonide/efomoterol fumarate dehydrate (symbicort): This medication is a combination of a long acting Beta 2 adrenergic receptor agonist and an inhaled corticosteroid. This medication is considered to be a maintenance therapy for the COPD patients. The inhaled corticosteroid or budesonide, has anti-inflammatory properties which help to reduce the inflammation of the bronchial airways and facilities better air passage. And formoterol is the long acting beta agonist bronchodilator which relaxes the muscles and prevents any bronchospasm, hence it will help relaxing respiratory muscles of Robert and wil evade any chances of him going through bronchospasm (Agusti, 2014). There are two major contraindications of this medication, with any acute episodes of COPD where intensive measures are required this medication cannot be administered. In case of Robert, any hypersensitivity reaction to the components of this medication will be harmful as well if taking this medication. Adverse reactions to this medication include allergic reaction, adrenal insufficiency and even an increased risk of infection such as pneumonia. There are 2 nursing considerations for this medication when administering to Robert, risk for infection and hypersensitivity. Patient education includes explaining to Robert to never use budesonide or formoterol in case of acute bronchospasm. In case of exceeding wheezing, Robert should be instructed to seek out immediate medical attention due to the possibility of acute asthmatic attack (Agusti, 2014). Tiotropium: Tiotropium is another bronchial muscle relaxant which is used to prevent any wheezing or shortness of breath. This medication is an anticholinergic and it relaxes the muscles around the bronchi and will facilitate smoother air passage in case of Robert. The contraindication for this medication includes any hypersensitivity to anticholinergics. Along with that renal diseases in glaucoma also contraindicated against the administration of this medication (Wise et al., 2013). The adverse effects of this medication are constipation, nausea, muscular pain, and nosebleed. Robert will need to be educated about the possible side effects of this medication all diseases are the most plausible adverse reaction to this medicine. The nursing considerations include the fact that this medicine should only be taken to prevent bronchospasm for an ongoing broncos ransom attack this medication should not be taken (Wise et al., 2013). The main contributing factor behind the doctor changing Roberts medicine chart by replacing the symbicort with tritopium can be the fact that symbicort can only be used in regular cases of COPD, it has no noticeable effect on exception of subdivision patient had been going through. Along with that, the major side effects of symbicort is pneumonia, and as the patient has already been suffering with community-acquired pneumonia continuing symbicort can be very harmful for the patient. Hence, the doctor replaced Symbicort with Tiotropium, which is a more targeted and fast action relieving medicine mainly used for treating bronchospasm attacks and exacerbations that Robert has been having (Wise et al., 2013). Amoxicillin: Amoxicillin is a penicillin type antibiotic that is used to treat many bacterial infections including pneumonia by Streptococcus pneumonia, and it can be used to treat Robert. It is usually administered orally every 8 to 12 hours and dosage is dependent on the severity of the infection. The contraindications include any allergies to penicillin type antibiotics and any renal disease which can be aggravated due to administration of this medicine. As Robert had no past history of renal diseases mentioned, this antibiotic can be easily used for Robert. Adverse effects that Robert might encounter include nausea,vomiting, and diarrhea. Nursing considerations include patients with mononucleosis not been given this medication along with patients with any hepatic impairment. Care should also be taken to ensure that phenylalanine is present in the oral chewable tablets and suspensions given to Robert. Patient education includes teaching Robert to chew or crush the chewable tablets rather than swallowing it and to notify the carer in case of any aggravation or bloody urine (Torres et al., 2015). Ceftriaxone: This is another cephalosporone type medication that is used to treat this infection, and is a very common treatment option for pneumococcal infections for elderly patients like Robert. The contraindications include hypersensitivity and the risk of calcium ceftriaxone interaction, which is needed to be assessed before administering to Robert. The adverse effects that Robert can have include bronchospasm, diarrhea, and nausea. Nursing considerations include checking for any allergies reaction of shortness of breath that Robert might experience. In terms of patient education, Robert should be instructed to notify and seek attention in case of hypersensitive reaction (Martin-Loeches et al., 2010). Levoflaxone: It s a quilonone used to treat pneumococcal infections in case of penicillin resistant strains. The contraindications include hypersensitivity, diabetes, and renal disorders. The adverse effects that Robert may have include nausea, insomnia, diarrhea and headache. The nursing consideration for this are ensuring Robert not being allergic to quilonone compounds and should be run slowly to avoid stinging. The patient teaching must include informing Robert to refrain from taking vitamins and supplements long with the possible side effects (Postma et al., 2015). Psychosocial interventions for COPD: According to the case study, Robert has been suffering from Exacerbation of COPD and severe community acquired pneumonia which has is associated with suffering and restrictions which can eventually have a significant psychological burden on the patient. Psychosocial burden associated with co-mosbidities have been reported to have a huge impact on the recovery statistics and wellbeing of the patient, and can even alter the response of the patient to the treatment pathways. Administering psychotherapic intervention can help the patient overcome the issues effectively. The most common intervention is cognitive behavioral therapy which will help Robert deal with the stress. However another psycho social intervention is mindfulness based therapy, which is gaining popularity in case of such disorders as well according to Agusti (2014). Moreover, relaxing therapies like yoga and meditation sessions can also help Robert find strength to cope with the stress and regain control of his recovery with respect to the case study (Wong et al., 2014). The next results can be yielded by an integrative psychotherapic plan incorporating cognitive behavioral therapy, mindfulness based intervention and relaxation technoques; which can address the differential psychotherapic need of a critical patient like Robert. References: Agusti, A. (2014). The path to personalised medicine in COPD.Thorax,vol 69(9), pp 857-864. DOi: 10.1136/thoraxjnl-2014-205507 Agust, A., Edwards, L. D., Rennard, S. I., MacNee, W., Tal-Singer, R., Miller, B. E., ... Crim, C. (2012). Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype.PloS one,vol 7(5), e37483. Retrieved from https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0037483 Albert, R. K., Connett, J., Bailey, W. C., Casaburi, R., Cooper Jr, J. A. D., Criner, G. J., ... Make, B. (2011). Azithromycin for prevention of exacerbations of COPD.New England Journal of Medicine,365(8), pp 689-698. DOI: 10.1056/NEJMoa1104623. Almagro, P., Cabrera, F. J., Diez, J., Boixeda, R., Ortiz, M. B. A., Murio, C., Soriano, J. B. (2012). Comorbidities and short-term prognosis in patients hospitalized for acute exacerbation of COPD: the EPOC en Servicios de medicina interna (ESMI) study.Chest,vol 142(5), pp 1126-1133. Retrieved from https://journal.chestnet.org/article/S0012-3692(12)60613-8/abstract Bischoff, E. W., Hamd, D. H., Sedeno, M., Benedetti, A., Schermer, T. R., Bernard, S., ... Bourbeau, J. (2011). Effects of written action plan adherence on COPD exacerbation recovery.Thorax, vol66(1), pp 26-31. Retrieved from https://journal.chestnet.org/article/S0012-3692(12)60613-8/abstract Erb-Downward, J. R., Thompson, D. L., Han, M. K., Freeman, C. M., McCloskey, L., Schmidt, L. A., ... Martinez, F. J. (2011). Analysis of the lung microbiome in the healthy smoker and in COPD.PloS one,vol 6(2), e16384. Retrieved from https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0016384 Han, M. K., Agusti, A., Calverley, P. M., Celli, B. R., Criner, G., Curtis, J. L., ... Make, B. J. (2010). Chronic obstructive pulmonary disease phenotypes: the future of COPD.American journal of respiratory and critical care medicine,vol 182(5), pp 598-604. DOI: 10.1056/NEJMoa1406330 Johansson, N., Kalin, M., Tiveljung-Lindell, A., Giske, C. G., Hedlund, J. (2010). Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods.Clinical Infectious Diseases,vol 50(2), pp 202-209. doi.org/10.1086/648678 Kaptein, A. A., Fischer, M. J., Scharloo, M. (2014). Self-management in patients with COPD: theoretical context, content, outcomes, and integration into clinical care.International journal of chronic obstructive pulmonary disease,vol 9, pp 907. doi:10.2147/COPD.S49622 Martin-Loeches, I., Lisboa, T., Rodriguez, A., Putensen, C., Annane, D., Garnacho-Montero, J., ... Rello, J. (2010). Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia.Intensive care medicine,vol 36(4), pp 612-620. Doi: 10.1007/s00134-009-1730-y Musher, D. M., Thorner, A. R. (2014). Community-acquired pneumonia.New England Journal of Medicine,vol 371(17), pp 1619-1628. DOI: 10.1056/NEJMra1312885 Postma, D. F., Van Werkhoven, C. H., Van Elden, L. J., Thijsen, S. F., Hoepelman, A. I., Kluytmans, J. A., ... Oosterheert, J. J. (2015). Antibiotic treatment strategies for community-acquired pneumonia in adults.New England Journal of Medicine,vol 372(14), pp 1312-1323. DOI: 10.1056/NEJMoa1406330 Torres, A., Sibila, O., Ferrer, M., Polverino, E., Menendez, R., Mensa, J., ... Niederman, M. S. (2015). Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial.Jama,vol 313(7), pp 677-686. doi:10.1001/jama.2015.88 Vogelmeier, C., Hederer, B., Glaab, T., Schmidt, H., Rutten-van Mlken, M. P., Beeh, K. M., ... Fabbri, L. M. (2011). Tiotropium versus salmeterol for the prevention of exacerbations of COPD.New England Journal of Medicine,vol 364(12), pp 1093-1103. DOI: 10.1056/NEJMoa1008378 Wise, R. A., Anzueto, A., Cotton, D., Dahl, R., Devins, T., Disse, B., ... Pledger, G. (2013). Tiotropium Respimat inhaler and the risk of death in COPD.New England Journal of Medicine,vol 369(16), pp 1491-1501. DOI: 10.1056/NEJMoa1303342 Wong, S. S., Abdullah, N., Abdullah, A., Liew, S. M., Ching, S. M., Khoo, E. M., ... Chia, Y. C. (2014). Unmet needs of patients with chronic obstructive pulmonary disease (COPD): a qualitative study on patients and doctors.BMC family practice,vol 15(1), pp 67. Doi: 10.1186/1471-2296-15-67